1. Home
  2. MDWD vs VRA Comparison

MDWD vs VRA Comparison

Compare MDWD & VRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • VRA
  • Stock Information
  • Founded
  • MDWD 2000
  • VRA 1982
  • Country
  • MDWD Israel
  • VRA United States
  • Employees
  • MDWD N/A
  • VRA N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • VRA Apparel
  • Sector
  • MDWD Health Care
  • VRA Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • VRA Nasdaq
  • Market Cap
  • MDWD 172.6M
  • VRA 163.9M
  • IPO Year
  • MDWD 2014
  • VRA 2010
  • Fundamental
  • Price
  • MDWD $16.48
  • VRA $5.22
  • Analyst Decision
  • MDWD Strong Buy
  • VRA Strong Buy
  • Analyst Count
  • MDWD 1
  • VRA 1
  • Target Price
  • MDWD $28.00
  • VRA $6.00
  • AVG Volume (30 Days)
  • MDWD 46.6K
  • VRA 180.8K
  • Earning Date
  • MDWD 11-26-2024
  • VRA 12-04-2024
  • Dividend Yield
  • MDWD N/A
  • VRA N/A
  • EPS Growth
  • MDWD N/A
  • VRA N/A
  • EPS
  • MDWD N/A
  • VRA 0.02
  • Revenue
  • MDWD $20,141,000.00
  • VRA $439,677,000.00
  • Revenue This Year
  • MDWD $30.16
  • VRA N/A
  • Revenue Next Year
  • MDWD $18.44
  • VRA $7.84
  • P/E Ratio
  • MDWD N/A
  • VRA $213.78
  • Revenue Growth
  • MDWD N/A
  • VRA N/A
  • 52 Week Low
  • MDWD $8.41
  • VRA $4.38
  • 52 Week High
  • MDWD $24.00
  • VRA $8.32
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 44.78
  • VRA 51.67
  • Support Level
  • MDWD $15.53
  • VRA $4.96
  • Resistance Level
  • MDWD $16.85
  • VRA $5.49
  • Average True Range (ATR)
  • MDWD 0.69
  • VRA 0.16
  • MACD
  • MDWD -0.07
  • VRA -0.01
  • Stochastic Oscillator
  • MDWD 32.87
  • VRA 48.44

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About VRA Vera Bradley Inc.

Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.

Share on Social Networks: